Green Tea Catechins as Neuroprotective Agents: Systematic Review of the Literature in Animal Pre-Clinical Trials.
Studies have identified dementia of the Alzheimer’s type to be the most prevalent form of dementia. The AD dementia has therefore become the most well-known type of dementia chiefly associated with older age.
The behavioural and cognitive onset of AD can be slow and gradual; it predominately manifests itself as a slow but progressive cognitive decline. Furthermore, there is no one universally accepted neuropathologic criteria to differentiate AD from healthy brain ageing primarily because AD is a complex neurodegenerative dementing illness. However, the fundamental neuropathologic features of AD, based on the post-mortem examination of patients’ brains, include reduced brain volume, enlarged ventricular spaces, region specific neurofibrillary tangles and neuritic amyloid plaques. The exact causative factor for these brain changes still remains unknown. However, the final
resulting physiological outcome is death of neural cells which causes severe cognitive impairment and eventually death of the patient suffering from AD.
The recent advances in drug development as well as more identifiable characteristics of neurodegeneration have set a path for the utilization of drugs that exhibit free radical scavenging and iron-chelating properties. These compounds can consequently serve as potential treatment of neurodegeneration and act as vehicle mediated “backbones” for human trials on suppressing the development of AD and Parkinson’s disease alike. These compounds can consequently serve as potential treatment of neurodegeneration and act as vehicle mediated “backbones” for human trials on suppressing the development of AD and Parkinson’s disease alike. The utilization of pure EGCG and more complex GTC mixtures in the prevention of neurodegeneration.
Adv Food Technol Nutr Sci Open J. 2015; 1(2): 48-57. doi: 10.17140/AFTNSOJ-1-108
